Vir Biotechnology, Inc. (VIR)
- Previous Close
9.73 - Open
9.76 - Bid 9.67 x 500
- Ask 9.75 x 100
- Day's Range
9.60 - 9.89 - 52 Week Range
7.61 - 27.48 - Volume
551,309 - Avg. Volume
982,479 - Market Cap (intraday)
1.318B - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
-- - EPS (TTM)
-4.01 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
32.29
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.
www.vir.bioRecent News: VIR
Performance Overview: VIR
Trailing total returns as of 5/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VIR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VIR
Valuation Measures
Market Cap
1.32B
Enterprise Value
295.17M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
29.77
Price/Book (mrq)
0.86
Enterprise Value/Revenue
6.71
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-16.73%
Return on Equity (ttm)
-30.67%
Revenue (ttm)
79.6M
Net Income Avi to Common (ttm)
-539.44M
Diluted EPS (ttm)
-4.01
Balance Sheet and Cash Flow
Total Cash (mrq)
1.15B
Total Debt/Equity (mrq)
7.82%
Levered Free Cash Flow (ttm)
-612.25M
Research Analysis: VIR
Company Insights: VIR
VIR does not have Company Insights